Navigation Links
BPA alters development of in vitro ova and could increase risk of Down syndrome

Researchers at Universitat Autnoma de Barcelona, in collaboration with the Vall d'Hebron Hospital Fetal Tissue Bank, the Department of Gynaecology and the Research Unit of Paediatric Endocrinology, analysed the effects of Bisphenol A (BPA), a polymer widely used to manufacture plastics, in an in vitro culture of ovaries. The research demonstrated that exposure to this substance gravely altered the development of oocytes and future ova, possibly diminishing the fertility of a woman's offspring and at the same time increasing the risk of Down Syndrome in following generations.

The research, published in Human Reproduction, was carried out with a culture of 21,570 in vitro oocytes. Results demonstrated that exposure to Bisphenol A in concentration levels permitted by health authorities is harmful to the fetus. BPA reduces the number of oocytes (cells which develop into ova) and therefore can affect negatively a woman's fertility and double the risk of chromosome exchange during the cell division process. Specific observations of chromosome 21 in the development of 90 oocytes revealed that exposure to BPA could increase the risk of Down Syndrome in the future offspring of the fetus.

The research provides conclusive data for the debate on how BPA affects the health of individuals. Previous studies on mice and worms demonstrated that reproduction is affected and that exposure to BPA during gestation affects the viability and quality of the cells which later become ova developing in the fetus.

For the first time, human cells were used in a research to analyse the process of cell division of the oocytes - meiosis - in which chromosomes join and exchange material, i.e. meiotic recombination. Oocytes were cultured for 7, 14 or 21 days in different environments, with the presence of BPA and in control cultures without the substance. Data obtained in vitro with human cells was practically identical to that obtained with in vivo animal models, while the effects on meiotic recombination, which could lead to the appearance of Down Syndrome, in humans are even greater than those observed in mice.

"According to our results, BPA does not directly affect the fertility of pregnant women, but that of their daughters and granddaughters. It is a multigenerational effect", explains UAB professor Montserrat Garcia Calds, director of the research. She goes on to say that "the increase in oocyte mortality in the fetus could diminish ovarian reserve numbers and the quality of the future mother's ova. At the same time, alterations in the recombination of chromosomes in the process of cell division increase the possibility of numerical alterations, such as monosomy (only copy of a chromosome in embryo cells) or trisomy (three copies)."

Concentration levels applied in the experiments were within the safety limits marked by European (EFSA) and US (EPA) authorities. The research therefore suggests that staying within legal limits does not imply that exposure to the substance is innocuous.

"We are exposed to BPA on a daily basis, mainly through oral exposure, since we can find it in lunch boxes, beverage bottles and food storage containers", Miguel ngel Brieo-Enrquez reminds us. First author of the article, Brieo-Enrquez, from the University of San Luis Potos, Mexico, is now researcher at the UAB Department of Cell Biology, Physiology and Immunology. According to him, "although we generally metabolise the substance, pregnant women retain more fluids and the fetus could be affected by high concentration levels."


Contact: Montserrat Garcia Caldes
Universitat Autonoma de Barcelona

Related medicine news :

1. Air pollution alters immune function, worsens asthma symptoms
2. IU researchers: Chemotherapy alters brain tissue in breast cancer patients
3. A high-fat diet alters crucial aspects of brain dopamine signaling
4. Barbara Walters Prognosis Is Excellent, Doctors Say
5. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
6. NIDA Avant-Garde-Medications Development Award winners announced
7. Transformative NIH grant will support development of tissue regeneration therapeutics
8. New strategy likely to speed drug development for rare cancers
9. Prenatal exposure to phthalates linked to decreased mental and motor development
10. Memory Development Incomplete Until Adulthood: Study
11. Researchers developing new test to measure risk for birth defects and neuro-developmental disorders
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: